花旗:上调三生制药目标价至13港元 评级升至“买入”

新浪港股
Mar 27, 2025
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  花旗发布研报称,三生制药(01530)去年收入同比升17%至91亿元人民币,纯利同比升35%至21亿元人民币。集团预测今年收入增长达两位数。该行将三生制药今年收入及盈利预测分别上调12%及34%,明年收入及盈利预测分别上调17%及43%,将其目标价由6.3港元上调至13港元,评级由“中性”升至“买入”。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:史丽君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10